Quarterly Report (10-q)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For quarterly period ended November 30, 2015

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________

Commission file number 333-127953

SOLARWINDOW TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

Nevada		59-3509694
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

10632 Little Patuxent Parkway, Suite 406 Columbia, Maryland		21044
(Address of principal executive offices)		(Zip Code)

(800) 213-0689

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	¨	Smaller reporting company	x
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in 12b-2 of the Exchange Act). Yes o No x

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: 26,944,721 shares of common stock, par value $0.001, were outstanding on January 7, 2016.

SOLARWINDOW TECHNOLOGIES, INC.

FORM 10-Q

For the Quarterly Period Ended November 30, 2015

Table of Contents

PART I FINANCIAL INFORMATION

Item 1.	Consolidated Financial Statements (Unaudited)	3

	Consolidated Balance Sheets	3

	Consolidated Statements of Operations	4

	Consolidated Statements of Stockholders' Equity (Deficit)	5

	Consolidated Statements of Cash Flows	6

	Notes to Consolidated Financial Statements	7

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	17

Item 4.	Controls and Procedures	21

PART II OTHER INFORMATION

Item 6.	Exhibits	22

Signatures		23

Certifications

PART I - FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements (Unaudited)

SOLARWINDOW TECHNOLOGIES, INC.
CONSOLIDATED BALANCE SHEETS
NOVEMBER 30, 2015 AND AUGUST 31, 2015

	November 30,			August 31,
	2015			2015
	(Unaudited)
ASSETS
Current assets
Cash and cash equivalents	$	169,057		$	228,465
Deferred research and development costs		23,443			106,135
Prepaid expenses and other current assets		29,020			21,152
Total current assets		221,520			355,752

Equipment, net of accumulated depreciation of $30,531 and $27,751, respectively		30,055			30,535
Total assets	$	251,575		$	386,287

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

Current liabilities
Accounts payable	$	90,123		$	97,438
Interest payable to related party		514,065			443,498
Bridge note, net of discount of $0 and $6,516		600,000			593,484
Convertible promissory notes payable to related party, net of discount of $623,558 and $879,808, respectively		2,776,447			2,120,192
Total current liabilities		3,980,635			3,254,612

Commitments and contingencies

Stockholders' equity (deficit)
Preferred stock: $0.10 par value; 1,000,000 shares authorized, no shares issued and outstanding		-			-
Common stock: $0.001 par value; 300,000,000 shares authorized, 26,572,615 shares issued and outstanding at November 30, 2015 and August 31, 2015		26,572			26,572
Additional paid-in capital		26,607,331			26,144,117
Retained deficit		(30,362,963	)		(29,039,014	)
Total stockholders' equity (deficit)		(3,729,060	)		(2,868,325	)
Total liabilities and stockholders' equity (deficit)	$	251,575		$	386,287

(The accompanying notes are an integral part of these consolidated financial statements)

SOLARWINDOW TECHNOLOGIES, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
FOR THE THREE MONTHS ENDED NOVEMBER 30, 2015 AND 2014

	Three Months Ended November 30,
	2015			2014

Revenue	$	-		$	-

Operating expense
Selling, general and administrative		441,694			566,291
Research and development		148,922			179,321
Total operating expense		590,616			745,612

Loss from operations		(590,616	)		(745,612	)

Other income (expense)
Interest expense		(70,567	)		(55,727	)
Accretion of debt discount		(662,766	)		(2,457,910	)
Total other income (expense)		(733,333	)		(2,513,637	)

Net loss	$	(1,323,949	)	$	(3,259,249	)

Basic and Diluted Loss per Common Share	$	(0.05	)	$	(0.13	)

Weighted average number of common shares outstanding - basic and diluted		26,572,615			24,308,495

(The accompanying notes are an integral part of these consolidated financial statements)

SOLARWINDOW TECHNOLOGIES, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)
FOR THE THREE MONTHS ENDED NOVEMBER 30, 2015 AND YEAR ENDED AUGUST 31, 2015

					Additional						Total Stockholders'
	Common Stock				Paid-in			Retained			Equity
	Shares		Amount		Capital			Deficit			(Deficit)

Balance, August 31, 2014		24,306,612	$	24,306	$	20,872,345		$	(20,946,270	)	$	(49,619	)

Stock based compensation related to restricted stock issuance		60,000		60		83,940			-			84,000
Stock based compensation due to common stock purchase options		-		-		436,774			-			436,774
Exercise of Series G warrants		454,787		455		(455	)		-			-
Exercise of Series H warrants		1,751,216		1,751		1,451,763			-			1,453,514
Discount on convertible promissory note due to detachable warrants		-		-		3,000,000			-			3,000,000
Discount on $600,000 bridge loan due to detachable warrants		-		-		299,750			-			299,750
Net loss for the year ended August 31, 2015		-		-		-			(8,092,744	)		(8,092,744	)
Balance, August 31, 2015		26,572,615		26,572		26,144,117			(29,039,014	)		(2,868,325	)

Stock based compensation due to common stock purchase options		-		-		63,214			-			63,214
Discount on convertible promissory note due to detachable warrants		-		-		234,360			-			234,360
Discount on convertible promissory note due to beneficial conversion feature		-		-		165,640			-			165,640
Net loss for the three months ended November 30, 2015		-		-		-			(1,323,949	)		(1,323,949	)
Balance, November 30, 2015 (Unaudited)		26,572,615	$	26,572	$	26,607,331		$	(30,362,963	)	$	(3,729,060	)

(The accompanying notes are an integral part of these consolidated financial statements)

SOLARWINDOW TECHNOLOGIES, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
FOR THE THREE MONTHS ENDED NOVEMBER 30, 2015 AND 2014

	Three Months Ended November 30,
	2015			2014
Cash flows from operating activities
Net loss	$	(1,323,949	)	$	(3,259,249	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation		2,780			1,831
Stock based compensation expense		63,214			157,646
Accretion of debt discount		662,766			2,457,910
Changes in operating assets and liabilities:
Decrease (increase) in deferred research and development costs		82,692			-
Decrease (increase) in prepaid expenses and other current assets		(7,868	)		(7,998	)
Increase (decrease) in accounts payable		(7,315	)		75,828
Increase (decrease) in accrued liabilities		70,567			55,727
Net cash used in operating activities		(457,113	)		(518,305	)

Cash flows from investing activity
Purchase of equipment		(2,300	)		(14,208	)
Net cash used in investing activity		(2,300	)		(14,208	)

Cash flows from financing activities
Proceeds from the exercise of warrants		-			3,242
Proceeds from promissory notes		400,005			-
Net cash provided by financing activities		400,005			3,242

Decrease in cash and cash equivalents		(59,408	)		(529,271	)

Cash and cash equivalents at beginning of period		228,465			785,237

Cash and cash equivalents at end of period	$	169,057		$	255,966

Supplemental disclosure of cash flow information:
Interest paid in cash	$	-		$	-
Income taxes paid in cash	$	-		$	-

Supplemental disclosure of non-cash transactions:
Debt discount recorded for value of warrants issued	$	234,360		$	3,000,000
Debt discount recorded for beneficial conversion feature	$	165,640		$	-

(The accompanying notes are an integral part of these consolidated financial statements)

SOLARWINDOW TECHNOLOGIES, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - Basis of Presentation, Organization, Recent Accounting Pronouncements and Going Concern

Basis of Presentation

The unaudited financial statements of SolarWindow Technologies, Inc. (the "Company") as of November 30, 2015, and for the three months ended November 30, 2015 and 2014, have been prepared in accordance with accounting principles generally accepted in the United States for interim financial reporting and include the Company's wholly-owned subsidiaries, Kinetic Energy Corporation ("KEC"), and New Energy Solar Corporation ("New Energy Solar"). Accordingly, they do not include all of the disclosures required by accounting principles generally accepted in the United States for complete financial statements and should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended August 31, 2015, as filed with the Securities and Exchange Commission as part of the Company's Form 10-K. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the interim financial information have been included. The Company did not record an income tax provision during the periods presented due to net taxable losses. The results of operations for any interim period are not necessarily indicative of the results of operations for the entire year.

Organization

SolarWindow Technologies, Inc. was incorporated in the State of Nevada on May 5, 1998, under the name "Octillion Corp." On December 2, 2008, the Company amended its Articles of Incorporation to effect a change of name to New Energy Technologies, Inc. Effective as of March 9, 2015, the Company amended its Articles of Incorporation to change its name to SolarWindow Technologies, Inc. The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Kinetic Energy Corporation ("KEC") and New Energy Solar Corporation.

KEC was incorporated on June 19, 2008, in the State of Nevada and holds the patents related to the Company's MotionPower™ technology. The Company's business activities related to the MotionPower™ technology are conducted through KEC.

New Energy Solar was incorporated on February 9, 2009, in the State of Florida and entered into agreements with The University of South Florida Research Foundation ("USF") to sponsor research related to the Company's SolarWindow™ technology. On February 18, 2015, the Company terminated the license agreement entered into with USF which originated on June 21, 2010.

On March 9, 2015, the Company changed its name to "SolarWindow Technologies, Inc." in order to appropriately align the corporate name and brand identity. The Company's ticker symbol changed to WNDW.

The Company has been developing two (2) sustainable electricity generating systems. These novel technologies are branded as SolarWindow™ and MotionPower™. On March 2, 2015, the Company announced its exclusive focus on SolarWindow™.

The Company's SolarWindow™ technology provides the ability to harvest light energy from the sun and artificial sources and generate electricity from a see-through, semi-transparent, coating of organic photovoltaic solar cells. The Company's SolarWindow™ transparent electricity generating coatings are the subject of patent pending technologies. Initially being developed for application on glass surfaces, SolarWindow™ coatings could potentially be used on any of the more than 85 million commercial and residential buildings in the United States alone.

The Company's SolarWindow™ product development programs involve ongoing research and development efforts, and the commitment of significant resources to support the extensive invention, design, engineering, testing, prototyping, and intellectual property initiatives carried-out by its contract engineers, scientists, and consultants. As such, the Company's activities are subject to significant risks and uncertainties, including failing to secure additional funding to operationalize the Company's technology before another company develops similar technology and products.

Recent Accounting Pronouncements

In February 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2015-02, "Amendments to the Consolidation Analysis", which amends the consolidation requirements in ASC 810 and significantly changes the consolidation analysis required under U.S. GAAP relating to whether or not to consolidate certain legal entities. Early adoption is permitted. The Company's effective date for adoption is January 1, 2016. The Company does not expect this accounting update to have a material effect on its consolidated financial statements in future periods, although that could change.

In January 2015, the FASB issued ASU 2015-01, "Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items", which eliminates the concept from U.S. GAAP the concept of an extraordinary item. Under the ASU, an entity will no longer (1) segregate an extraordinary item from the results of ordinary operations; (2) separately present an extraordinary item on its income statement, net of tax, after income from continuing operations; or (3) disclose income taxes and earnings-per-share data applicable to an extraordinary item. Early adoption is permitted. The Company's effective date for adoption is January 1, 2016. The Company does not expect this accounting update to have a material effect on its consolidated financial statements in future periods, although that could change.

In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205 40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern, which is intended to define management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosures. Specifically, ASU 2014-15 provides a definition of the term substantial doubt and requires an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). It also requires certain disclosures when substantial doubt is alleviated as a result of consideration of management's plans and requires an express statement and other disclosures when substantial doubt is not alleviated. The new standard will be effective for reporting periods beginning after December 15, 2016, with early adoption permitted. Management does not expect the adoption of ASU 2014-15 to have a material impact on our financial statements and disclosures.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (ASU 2014-09), which supersedes most existing revenue recognition guidance under US GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP. The standard is effective for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company does not expect this accounting update to have a material effect on its consolidated financial statements in future periods.

The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Company's previous fiscal year may be applicable, the Company has not identified any standards that the Company believes merit further discussion. The Company believes that none of the new standards will have a significant impact on the financial statements.

Going Concern

The Company does not have any commercialized products and has not generated any revenue since inception. The Company has an accumulated deficit of $30,362,963 as of November 30, 2015, and does not have positive cash flows from operating activities. The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America, which contemplates continuation of the Company as a going concern, which is dependent upon the Company's ability to establish itself as a profitable business.

In its report with respect to the Company's financial statements for the year ended August 31, 2015, the Company's independent auditors expressed substantial doubt about the Company's ability to continue as a going concern. Because the Company has not yet generated revenues from its operations and does not expect to do so in the near future, its ability to continue as a going concern is wholly dependent upon its ability to obtain additional financing. Currently, the Company is seeking additional financing but has no commitments to obtain any such financing, and there can be no assurance that financing will be available in amounts or on terms acceptable to the Company, if at all.

As of November 30, 2015, the Company had cash of $169,057 and commitments for an additional loan of $150,000. Based upon its current and near term anticipated level of operations and expenditures, the Company believes that cash on hand should be sufficient to enable it to continue operations through January 2016.

If adequate funds are not available on reasonable terms, or at all, it would result in a material adverse effect on the Company's business, operating results, financial condition and prospects. In particular, the Company may be required to delay, reduce the scope of or terminate its research programs, sell rights to its SolarWindow™ technology and/or MotionPower^TM technology or other technologies or products based upon such technologies, or license the rights to such technologies or products on terms that are less favorable to the Company than might otherwise be available.

In view of these conditions, the ability of the Company to continue as a going concern is in substantial doubt and dependent upon achieving a profitable level of operations and on the ability of the Company to obtain necessary financing to fund ongoing operations. These consolidated financial statements do not give effect to any adjustments which will be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying consolidated financial statements.

NOTE 2 - Debt

December 7, 2015, $550,000 Bridge Loan

On December 7, 2015, the Company entered into a Bridge Loan Agreement (the "December 2015 Loan Agreement") with Kalen Capital Corporation (the "Investor"), a private corporation owning in excess of 10% of the Company's issued and outstanding shares of common stock. Pursuant to the December 2015 Loan Agreement, the Company may borrow up to $550,000; of which $400,005 was advanced on October 7, 2015 (the "October 2015 Loan Advance") and $150,000 on December 22, 2015 (the "December 2015 Loan Advance") (collectively, the "December 2015 Loan"). Following the occurrence of an event of default, as further specified in the December 2015 Loan Agreement; the annual interest rate would increase to 18%. The December 2015 Loan was evidenced by a promissory note with an annual interest rate of 10%, compounded quarterly, and a maturity date of the earlier of: (a) the closing of any equity financing by the Company in excess of $3,000,000, or (b) September 1, 2016. The December 2015 Loan is convertible at any time into shares of common stock at a conversion price equal to 85% of the thirty (30) day volume weighted average price of the Company's common stock. Also, as a condition to the Investor's entry into the December 2015 Loan Agreement, the Company issued the Investor a Series M Stock Purchase Warrant to purchase up to 275,000 shares of the Company's common stock for a period of five (5) years, with an exercise price of $2.34; the Series M Warrant contains a provision allowing the Investor to exercise the Series M Warrant on a cashless basis as further set forth therein.

The Company first allocated October 2015 Loan Advance principal between the October 2015 Loan Advance and the Series M Warrants based upon their relative fair values. The estimated fair value of the Series M Warrants was calculated using the Black-Scholes option pricing model and the following assumptions: market price of common stock - $3.01 per share; estimated volatility - 79%; 5-year risk free interest rate - 1.67%; expected dividend rate - 0% and expected life - 5 years. This resulted in allocating $234,360 to the Series M Warrants and $165,640 to the October 2015 Loan Advance. Next, the intrinsic value of the beneficial conversion feature was computed as the difference between the fair value of the common stock issuable upon conversion of the October 2015 Loan Advance and the total price to convert based on the effective conversion price. The calculated intrinsic value was $348,890. As this amount resulted in a total debt discount that exceeds the October 2015 Loan Advance proceeds, the amount recorded for the beneficial conversion feature was limited to principal amount of the October 2015 Loan Advance. The resulting $400,005 discount is being accreted over the 9 month term of the October 2015 Loan Advance.

March 4, 2015, $600,000 Bridge Loan

On March 4, 2015, the Company entered into a Bridge Loan Agreement (the "Bridge Loan Agreement") with 1420468 Alberta Ltd. (the "Creditor") pursuant to which the Company borrowed $600,000 at an annual interest rate of 7% (the "March 2015 Loan"), compounded quarterly; following the occurrence of an event of default, as further specified in the Bridge Loan Agreement, the annual interest rate would increase to 15%. The March 2015 Loan was evidenced by a promissory note with a maturity date of the earlier of: (a) the closing of any equity financing by the Company in excess of $600,000, or (b) September 4, 2015. As a condition to the Creditor's entry into the Bridge Loan Agreement, the Company issued the Creditor a Series L Stock Purchase Warrant to purchase up to 500,000 shares of the Company's common stock, which are exercisable from September 5, 2015 through March 4, 2020, with an exercise price of $1.20; the Series L Warrant contains a provision allowing the Creditor to exercise the Series L Warrant on a cashless basis as further set forth therein.

The fair value of the Series L Warrant was $1.198 per share and was calculated using the Black-Scholes option pricing model with the following assumptions: market price of common stock - $1.78 per share; estimated volatility - 76%; risk free interest rate - 1.55%; expected dividend rate - 0% and expected life - 4.5 years. This resulted in allocating $299,750 to the Series L Warrant and $300,250 to the March 2015 Loan. As a result, on March 4, 2015, the Company recorded a debt discount of $299,750 which is being accreted over the term of the March 2015 Loan.

On December 7, 2015, the maturity date of the March 2015 Loan was extended to December 31, 2016. As consideration the Company issued the Creditor a Series M Stock Purchase Warrant to purchase up to 100,000 shares of the Company's common stock through December 7, 2020, at an exercise price of $2.34 per share; the Series M Warrant contains a provision allowing the Creditor to exercise the Series M Warrant on a cashless basis as further set forth therein. The Company also agreed to extend the expiration date of the Series L Warrant to December 7, 2020.

Interest expense and accretion of the debt discount related to the March 2015 Loan amounted to $10,835 and $6,516, respectively, during the three months ended November 30, 2015.

Convertible Promissory Note

On October 7, 2013 (the "Closing Date"), the Company entered into a Bridge Loan Agreement (the "2013 Loan Agreement") with the Investor. Pursuant to the 2013 Loan Agreement, the Company received proceeds of $3,000,000 and issued a 7% unsecured Convertible Promissory Note (the "2013 Note") due on October 6, 2014, with interest compounded quarterly and issued a Series I Stock Purchase Warrant (the "Series I Warrant") for the purchase up to 921,875 shares of the Company's common stock at an initial exercise price of $1.37 for a period of five (5) years. The Series I Warrant is exercisable on a "cashless basis" and was unexercised as of November 30, 2015. According to the original terms of the 2013 Loan Agreement, the Investor may have elected, in its sole discretion, to convert all or any portion of the outstanding principal amount of the 2013 Note, and any or all accrued and unpaid interest thereon into units, with each unit consisting of (a) one share of common stock; (b) one Series J Stock Purchase Warrant for the purchase of one share of common stock (the "Series J Warrant"); and (c) one Series K Stock Purchase Warrant for the purchase of one share of common stock (the "Series K Warrant").

On November 10, 2014, the Company entered into an Amended Bridge Loan Agreement (the "2015 Loan Agreement") with Investor pursuant to which the Company and Investor amended the 2013 Loan Agreement by amending the 2013 Note to extend the maturity date to December 31, 2015 (the "Amended Note"). According to the terms of the 2015 Loan Agreement, the Investor may elect, in its sole discretion, to convert all or any portion of the outstanding principal amount of the Amended Note, and any or all accrued and unpaid interest thereon into units of the Company's equity securities (collectively, the "Units"), with each Unit consisting of (a) one share of common stock; and (b) one Series L Stock Purchase Warrant for the purchase of one share of common stock. The conversion price for each Unit is the lesser of (i) $1.37; or (ii) 70% of the 20 day average closing price of the Company's common stock prior to conversion, subject to a floor of $1.00 with the exercise price of each Series L Warrant included in the Units issued upon conversion being equal to sixty percent (60%) of the 20 day average closing price of the Company's common stock prior to conversion. The Series L Warrant will be exercisable for a period of five years from the date of issuance and will be exercisable on a cashless basis.

In order to induce Investor to enter into the 2015 Loan Agreement and extend the maturity date of the 2013 Note, the Company issued a Series J Warrant to purchase 3,110,378 shares of its common stock at an exercise price of $1.12 and a Series K Warrant to purchase 3,110,378 shares of its common stock at an exercise price of $1.20. Each of the Series J Warrant and Series K Warrant is exercisable through November 9, 2019 and contains a provision allowing the Investor to exercise the warrant on a cashless basis as further set forth therein.

For accounting purposes, the modification to the 2013 Loan Agreement did not result in a gain or loss, as an extinguishment under accounting principles generally accepted in the United States, due to the related party nature of the transaction. As described above, the 2015 Loan Agreement resulted in the issuance of a Series J Warrant and a Series K Warrant. Prior to the 2015 Loan Agreement, the Series J and Series K Warrants were to be issued to the Investor only upon the Investor's election to convert the 2013 Note (according to the original terms of the 2013 note). Also as a result of the 2015 Loan Agreement, the principal amount of the Amended Note and accrued interest thereon is convertible into Units. As such, the fair value of the Series L Warrant, representing the value exchanged for the modification of the conversion option associated with the 2013 Loan Agreement, was recognized as a discount to the Amended Note with a corresponding increase in additional paid-in capital. The fair value of the Series L Warrant was $1.16 per share. The fair value of the Series L Warrant was calculated using the Black-Scholes option pricing model and the following assumptions: market price of common stock - $1.28 per share; estimated volatility - 138%; risk free interest rate - 1.57%; expected dividend rate - 0% and expected life - 5 years. Based on the terms of the Amended Note, 3,142,359 warrants were issuable on November 10, 2014 with a fair value of $3,645,137 (3,142,359 Warrants x $1.16 per share). The debt discount is limited to the face value of the Amended Note. As a result, on November 10, 2014, the Company recorded a debt discount of $3,000,000 which is being accreted over the term of the Amended Note using the effective interest method.

Interest expense related to the 2013 Loan Agreement as amended amounted to $59,732 and $55,727 during the three months ended November 30, 2015 and 2014, respectively.

During the three months ended November 30, 2015 and 2014, the Company recognized $656,250 and $2,457,910, respectively, of accretion of debt discount. The 2014 expense of $2,457,910 includes $2,313,680 of accretion related to the debt discount originally recorded on the 2013 Note and $144,230 related to the Series L Warrant issuable pursuant to the 2015 Loan Agreement. The remaining debt discount related to the Series L Warrants and totaling $223,558 will be amortized during the quarter ended February 29, 2016.

NOTE 3 - Common Stock and Warrants

At November 30, 2015, the Company had 300,000,000 authorized shares of common stock with a par value of $0.001 per share, 26,572,615 shares of common stock outstanding and 3,332,498 shares reserved for issuance under the Company's 2006 Long-Term Incentive Plan (the "2006 Plan") as adopted and approved by the Company's Board of Directors (the "Board") on October 10, 2006 that provides for the grant of stock options to employees, directors, officers and consultants (See "NOTE 4 - Stock Options").

During the year ended August 31, 2015, the Company had the following common stock related transactions:

	·	issued 454,787 shares of common stock upon the cashless exercise of 625,000 Series G Warrants.

	·	issued 1,751,216 shares of common stock as a result of the exercise of Series H Warrants for which the Company received $1,453,514.

	·	issued 20,000 shares of common stock on January 26, 2015 to each of the Company's three directors pursuant to the 2006 Plan (60,000 shares total) valued at $1.40 per share, the closing price of the Company's common stock on the day the stock was granted (See "NOTE 6 - Related Party Transactions" below for additional information).

Warrants

Each of the Company's warrants outstanding entitles the holder to purchase one share of the Company's common stock for each warrant share held. A summary of the Company's warrants outstanding and exercisable as of November 30, 2015 and August 31, 2015 is as follows:

	Shares of Common Stock Issuable from Warrants Outstanding as of
Description	November 30, 2015		August 31, 2015		Exercise Price		Expiration
Series G		-		-	$	0.64	April 17, 2015
Series H		3,906		3,906	$	0.83	February 1, 2016
Series I		921,875		921,875	$	1.37	October 7, 2018
Series J		3,110,378		3,110,378	$	1.12	November 9, 2019
Series K		3,110,378		3,110,378	$	1.20	November 9, 2019
Series L		500,000		500,000	$	1.20	March 4, 2020
Total		7,646,537		7,646,537

The Series G Warrant was issued on April 17, 2012, as a condition to the Investor entering into a $1 million loan agreement during 2012 (the "2012 Loan"). On April 10, 2015, the Company issued 454,787 net shares pursuant to the cashless exercise of 625,000 Series G Warrants. The Company did not receive any funds from this exercise. A Series H Warrant to purchase 825,435 shares was issued in connection with the 2012 Loan conversion. Series H Warrants to purchase 937,499 shares were issued on February 1, 2013, in connection with the self-directed registered offering of 1,875,000 units. During the year ended August 31, 2013, two holders of Series H warrants exercised 7,812 warrants. The Series I Warrant was issued on October 7, 2013, in connection with the 2013 Loan Agreement. The Series J Warrant and Series K Warrant were issued on November 10, 2014 as a condition to the Investor entering into the 2015 Loan Agreement. In addition, there are a total of approximately 2,541,853 Series L Warrants issuable pursuant to the March 2015 Loan as described above under "NOTE 2 - Debt."

No warrants were issued, exercised or canceled during the three months ended November 30, 2015. During the year ended August 31, 2015, the Company received $1,453,514 upon the exercise of Series H Warrants for 1,751,216 shares.

NOTE 4 - Stock Options

Stock option grants pursuant to the 2006 Plan vest either immediately or over one to five years and expire ten years after the date of grant. Stockholders previously approved 5,000,000 shares for grant under the 2006 Plan, of which 3,332,498 remain available for grant and 326,667 were issued pursuant to the exercise of vested options as of November 30, 2015. All shares approved for grant and subsequently forfeited are available for future grant. The Company does not repurchase shares to fulfill the requirements of options that are exercised. The Company issues new shares when options are exercised.

The Company employs the following key weighted-average assumptions in determining the fair value of stock options, using the Black-Scholes option pricing model and the simplified method to estimate the expected term of "plain vanilla" options:

	Year Ended
	August 31, 2015
Expected dividend yield		-
Expected stock price volatility		137.5	%
Risk-free interest rate		1.90	%
Expected term (in years)		7.67
Exercise price	$	1.40
Weighted-average grant date fair-value	$	1.33

A summary of the Company's stock option activity for the three months ended November 30, 2015 and 2014 and related information follows:

	Number of Shares Subject to Option Grants			Weighted Average Exercise Price ($)		Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value ($)
Outstanding at August 31, 2014		1,325,837			2.68
Grants		15,000			1.40
Forfeitures		(73,335	)		2.46
Outstanding at August 31, 2015		1,267,502			2.68
Forfeitures		(16,667	)		5.94
Outstanding at November 30, 2015		1,250,835			2.63	7.21 years	$	651,292
Exercisable at November 30, 2015		693,335			2.43	6.44 years	$	556,417
Available for grant at November 30, 2015		3,332,498

The aggregate intrinsic value in the table above represents the total pretax intrinsic value for all "in-the-money" options (i.e. the difference between the Company's closing stock price on the last trading day of the period covered by this report and the exercise price, multiplied by the number of shares) that would have been received by the option holders had all in-the-money option holders exercised their vested options on November 30, 2015. The intrinsic value of the option changes based upon the fair market value of the Company's common stock. Since the closing stock price was $3.05 on November 30, 2015 and 1,200,834 outstanding options have an exercise price below $3.05 per share, as of November 30, 2015, there is intrinsic value to the Company's outstanding, in-the-money stock options.

The following table sets forth the share-based compensation cost resulting from stock option grants, including those previously granted and vesting over time, that were recorded in the Company's Consolidated Statements of Operations for the three months ended November 30, 2015 and 2014:

	Three Months Ended November 30,
	2015		2014
Stock Compensation Expense:
Selling general and administrative expense	$	61,556	$	154,133
R&D expense	$	1,658	$	3,513

As of November 30, 2015, the Company had $219,665 of unrecognized compensation cost related to unvested stock options which is expected to be recognized over a period of 2.25 years.

The following table summarizes information about stock options outstanding and exercisable at November 30, 2015:

	Stock Options Outstanding						Stock Options Exercisable
Range of Exercise Prices	Number of Shares Subject to Outstanding Options		Weighted Average Contractual Life (years)		Weighted Average Exercise Price		Number of Shares Subject To Options Exercise		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price
$0.80		15,000		7.06	$	0.80		15,000		7.06	$	0.80
1.40		15,000		9.05		1.40		7,500		9.05		1.40
1.65		320,000		3.98		1.65		320,000		5.77		1.65
2.30		2,500		6.41		2.30		2,500		6.41		2.30
2.50		10,000		5.35		2.50		10,000		5.35		2.50
2.55		33,334		2.78		2.55		33,334		2.78		2.55
2.90		805,000		8.16		2.90		255,000		8.14		2.90
4.98		16,667		2.28		4.98		16,667		2.28		4.98
5.94		33,334		5.07		5.94		33,334		5.07		5.94
Total		1,250,835		7.21	$	2.63		693,335		6.44	$	2.43

NOTE 5 - Net Loss Per Share

During the three months ended November 30, 2015 and 2014, the Company recorded a net loss. Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. The Company has not included the effects of warrants, stock options and convertible debt on net loss per share because to do so would be antidilutive.

Following is the computation of basic and diluted net loss per share for the three months ended November 30, 2015 and 2014:

	Three Months Ended
	November 30,
	2015			2014
Basic and Diluted EPS Computation
Numerator:
Loss available to common stockholders'	$	(1,323,949	)	$	(3,259,249	)
Denominator:
Weighted average number of common shares outstanding		26,572,615			24,308,495
Basic and diluted EPS	$	(0.05	)	$	(0.13	)

The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented:

Convertible debt		2,541,853			3,248,878
Warrants issuable upon conversion of debt (See "NOTE 2 - Convertible Promissory Note" above)		2,541,853			3,248,878
Warrants		7,646,537			9,518,851
Stock options		1,250,835			1,314,170
Total shares not included in the computation of diluted losses per share		13,981,078			17,330,777

NOTE 6 - Related Party Transactions

A related party with respect to the Company is generally defined as any person (i) (and, if a natural person, inclusive of his or her immediate family) that holds 10% or more of the Company's securities, (ii) that is part of the Company's management, (iii) that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.

The Company grants stock options and common stock for services rendered by certain individuals, including the Company's non-employee directors and sole officer, Mr. Conklin. During the three months ended November 30, 2015 and 2014, the Company recognized net compensation expense related to stock options issued to our non-employee directors and executive of $63,214 and $152,083, respectively.

The law firm of Sierchio & Partners, LLP (formerly Sierchio & Company, LLP), of which Joseph Sierchio, one of the Company's directors, is a principal, has provided counsel to the Company since its inception. During the three months ended November 30, 2015 and 2014, the law firm of Sierchio & Partners, LLP provided $46,965 and $48,910, respectively, of legal services. At November 30, 2015, the Company owed Sierchio & Partners, LLP $15,000 which is included in accounts payable.

On October 7, 2013, the Company entered into the 2013 Loan Agreement with Investor and on November 10, 2014, the Company and Investor entered into the 2015 Loan Agreement resulting in the extension of the 2013 Note's maturity date to December 31, 2015 and the issuance of a Series J Warrant to purchase 3,110,378 shares of our common stock and a Series K Warrant to purchase 3,110,378 shares of our common stock. For more information, see "NOTE 2 - Debt" above.

On December 7, 2015, the Company entered into a Bridge Loan Agreement with the Investor pursuant to which the Company may borrow up to $550,000; of which $400,000 was advanced on October 7, 2015. As a condition to the Investor's entry into the December 2015 Loan Agreement, the Company issued the Investor a Series M Stock Purchase Warrant to purchase up to 275,000 shares of the Company's common stock for a period of five (5) years, with an exercise price of $2.34. For more information, see "NOTE 2 - Debt" above.

During 2015, the Company received $765,156 upon the Investor's exercise of 921,875 Series H Warrants, for an equal number of shares, originally issued on February 1, 2013 pursuant to the Company's $1.2 million self-directed financing.

All related party transactions are recorded at the exchange amount established and agreed to between related parties and are in the normal course of business.

NOTE 7 - Subsequent Events

Management has reviewed material events subsequent of the quarterly period ended November 30, 2015 and prior to the filing of financial statements in accordance with FASB ASC 855 "Subsequent Events".

December 7, 2015, $550,000 Bridge Loan

On December 7, 2015, the Company entered into a Bridge Loan Agreement with the Investor pursuant to which the Company may borrow up to $550,000; of which $400,005 was advanced to the Company on October 7, 2015, and the remaining $150,000 was forwarded to the Company on December 22, 2015; see "Note 2 - Debt" above for additional information.

March 2015 $600,000 Loan Amendment and Related Warrant Transactions

The fair value of the Series M Warrant was $2.058 and was calculated using the Black-Scholes option pricing model and the following assumptions: exercise price - $2.34; market price of common stock - $3.01 per share; estimated volatility - 79%; risk free interest rate - 1.67%; expected dividend rate - 0% and expected life - 5 years. The Company recorded $205,800 as a debt discount related to the 100,000 Series M Warrants and will amortize through December 31, 2016.

Additionally, the expiration date of the currently outstanding Series L Warrant allowing the Creditor to purchase up to 500,000 shares of common stock was extended from March 4, 2020 to December 7, 2020. The difference in fair value of the Series L Warrant as a result of the extension of the expiration date was $33,000 and was calculated using the Black-Scholes option pricing model and the following assumptions: exercise price - $1.2; market price of common stock - $3.01 per share; estimated volatility - 79%; risk free interest rate - 1.67%; expected dividend rate - 0% and expected life - 5 years for the new warrant and 4.24 years for the original warrant. The Company recorded $33,000 as a debt discount related to the 500,000 Series L Warrant expiration date extension and will amortize through December 31, 2016.

2015 Loan Agreement

On December 31, 2015, the Company entered into a Second Amended Bridge Loan Agreement (the "2015 Second Amended Loan Agreement") with Investor pursuant to which the Company and Investor amended the 2015 Loan Agreement by amending the 2013 Note to extend the maturity date to December 31, 2017 (the "Second Amended Note").

In order to induce Investor to enter into the 2015 Second Amended Loan Agreement and extend the maturity date of the 2013 Note, the Company issued a Series N Warrant to purchase 767,000 shares of its common stock at an exercise price of $3.38. The Series N Warrant is exercisable through December 31, 2020 and contains a provision allowing the Investor to exercise the warrant on a cashless basis as further set forth therein.

Additionally, as consideration for Investor agreeing to extend the 2013 Note maturity date to December 31, 2017, the Company extended the maturity date of all of Investor's existing warrants, including the following:

	·	Series I Warrant to purchase 921,875 shares of common stock; maturity date extended from October 6, 2018 to December 31, 2020;

	·	Series J Warrant to purchase 3,110,378 shares of common stock; maturity date extended from November 9, 2019 to December 31, 2020;

	·	Series K Warrant to purchase 3,110,378 shares of common stock; maturity date extended from November 9, 2019 to December 31, 2020; and

	·	Series M Warrant to purchase 275,000 shares of common stock; maturity date extended from December 7, 2020 to December 31, 2020.

Exercise of Stock Purchase Options

On December 17, 2015, John Conklin, the Company's President & CEO, exercised 400,000 stock purchase options on a cashless basis resulting in the issuance of 195,139 shares of common stock.

On December 18, 2015, Joseph Sierchio, a director, exercised 86,670 stock purchase options on a cashless basis resulting in the issuance of 47,567 shares of common stock.

On December 18, 2015, Alastair Livesey, a director, exercised 70,000 stock purchase options on a cashless basis resulting in the issuance of 39,400 shares of common stock.

Modification #7 to the Cooperative Research and Development Agreement with

On December 28, 2015, the Company entered into Modification #7 to the Cooperative Research and Development Agreement ("Modification #7") with the Alliance for Sustainable Energy, LLC, operator of The National Renewable Energy Laboratory ("NREL") under its U.S. Department of Energy contract, previously entered into between the Company and NREL. The purpose of Modification #7 is to extend the date pursuant to which NREL's researchers will make use of the Company's exclusive intellectual property and NREL's background intellectual property in order to work towards specific product development goals. Specifically, the Company is preparing to commercialize the company's OPV-based SolarWindow™ transparent electricity-generating coatings for building-integrated photovoltaic (BIPV), and glass and flexible substrate applications. Under this Modification #7, the Company and NREL will work jointly towards achieving specific commercialization goals and objectives.

Director Stock Awards

On January 5, 2016, the Company compensated its directors by issuing 30,000 shares of common stock to each of its three directors for a total issuance of 90,000 shares. The closing price of our stock on the issuance date was $3.75 resulting in expense of $337,500. As part of the issuance, each of the directors entered into a lock-up agreement restricting the sale of 75% of the issued shares for a period of one year.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

This Report on Form 10-Q contains forward-looking statements which involve assumptions and describe our future plans, strategies, and expectations, and are generally identifiable by use of words such as "may," "will," "should," "expect," "anticipate," "estimate," "believe," "intend," or "project," or the negative of these words or other variations on these words or comparable terminology. These statements are expressed in good faith and based upon a reasonable basis when made, but there can be no assurance that these expectations will be achieved or accomplished.

Such forward-looking statements include statements regarding, among other things, (a) the potential markets for our technologies, our potential profitability, and cash flows, (b) our growth strategies, (c) expectations from our ongoing research and development activities, (d) anticipated trends in the technology industry, (e) our future financing plans, and (f) our anticipated needs for working capital. This information may involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from the future results, performance, or achievements expressed or implied by any forward-looking statements. These statements may be found under "Management's Discussion and Analysis of Financial Condition and Results of Operations" as well as in this Form 10-Q generally. Actual events or results may differ materially from those discussed in forward-looking statements as a result of various factors, including, without limitation, the matters described in this Form 10-Q generally. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements contained in this filing will in fact occur. In addition to the information expressly required to be included in this filing, we will provide such further material information, if any, as may be necessary to make the required statements, in light of the circumstances under which they are made, not misleading.

Although forward-looking statements in this report reflect the good faith judgment of our management, forward-looking statements are inherently subject to known and unknown risks, business, economic and other risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this report, other than as may be required by applicable law or regulation. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with the Securities and Exchange Commission which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect our actual results may vary materially from those expected or projected.

Except where the context otherwise requires and for purposes of this Form 10-Q only, "we," "us," "our," "Company," "our Company," and "SolarWindow" refer to SolarWindow Technologies, Inc., a Nevada corporation, and its consolidated subsidiaries.

Overview

We are a pre-revenue company developing our proprietary SolarWindow™ technology as the world's first-of-their-kind systems able to generate electricity on glass windows and flexible plastic while remaining see-through. Our SolarWindow™ technology provides the ability to harvest light energy from the sun and artificial sources and generate electricity from a see-through, semi-transparent, coating of OPV solar cells applied to glass and plastics.

We do not currently have any commercial products and there is no assurance that we will successfully be able to design, develop, manufacture, or sell any commercial products in the future.

Our product development programs involve ongoing research and development ("R&D") and product development efforts, and the commitment of significant resources to support the extensive invention, design, engineering, testing, prototyping, and intellectual property initiatives carried-out by our contract engineers, scientists, and consultants.

Ultimately, we plan to market any SolarWindow™ technology products through co-marketing, co-promotion, licensing and distribution arrangements with third party collaborators. We believe that this approach could provide immediate access to pre-existing distribution channels, therefore potentially increasing market penetration and commercial acceptance of our products and enabling us to avoid expending significant funds for development of a large sales and marketing organization.

We cannot accurately predict the amount of funding or the time required to successfully commercialize our SolarWindow™ technology. The actual cost and time required to commercialize our SolarWindow™ technology may vary significantly depending on, among other things, the results of our R&D efforts, the cost of developing, acquiring, or licensing various enabling technologies, changes in the focus and direction of our R&D programs, competitive and technological advances, the cost of filing, prosecuting, defending and enforcing claims with respect to patents, the regulatory approval process and manufacturing, marketing and other costs associated with commercialization of these technologies. Because of this uncertainty, even if financing is available to us, we may secure insufficient funding to effectuate our business plan.

As of November 30, 2015, we had negative working capital of $3,759,115, cash of $169,057 and commitments for an additional loan of $150,000. Based upon current and near term anticipated level of operations and expenditures, we believe that cash on hand should be sufficient to enable us to continue operations through January 2016. Management recognizes that in order for us to meet our capital requirements, and continue to operate, additional financing will be necessary. We expect to raise additional funds through private or public equity investment in order to expand the range and scope of its business operations. We will seek access to private or public equity but there is no assurance that such additional funds will be available for us to finance our operations on acceptable terms, if at all. If we are unable to raise additional capital or generate positive cash flow, it is unlikely that we will be able to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Research and Related Agreements

We are a party to certain agreements related to the development of our SolarWindow™ technology.

Stevenson-Wydler Cooperative Research and Development Agreement with the Alliance for Sustainable Energy

In efforts to advance the commercial development of the SolarWindow™ technology, on March 18, 2011, we entered into a CRADA with Alliance for Sustainable Energy, LLC ("Alliance"), the operator of NREL under its U.S. Department of Energy contract. Under terms of the CRADA, NREL researchers will make use of our exclusive intellectual property ("IP"), newly developed IP, and NREL's background IP in order to work towards specific product development goals. Under the terms of the CRADA, we agreed to reimburse Alliance for filing fees associated with all documented, out-of-pocket costs directly related to patent application preparation and filings, and maintenance of the patent applications.

On January 16, 2013, we entered into a modification to the CRADA for the purpose of extending the date pursuant to which NREL's researchers will make use of our exclusive IP and NREL's background IP. As part of the extension, we advanced $150,000 to Alliance as a retainer, which will be used once the development goals are met. Until such time, however, Alliance bills us monthly for R&D related costs as they are incurred.

On March 6, 2013, we entered into Phase II of our CRADA with Alliance. Under the terms of the agreement, researchers will additionally work towards:

	·	further improving SolarWindow™ technology efficiency and transparency;

	·	optimizing electrical power (current and voltage) output;

	·	optimizing the application of the active layer coatings which make it possible for SolarWindow™ coatings to generate electricity on glass surfaces;

	·	developing improved electricity-generating coatings by enhancing performance, processing, reliability, and durability;

	·	optimizing SolarWindow™ coating performance on flexible substrates; and

	·	developing high speed and large area roll-to-roll (R2R) and sheet-to-sheet (S2S) coating methods required for commercial-scale building integrated photovoltaic ("BIPV") products and windows.

Results of Operations

Three Months Ended November 30, 2015 Compared with the Three Months Ended November 30, 2014

Operating Expenses

A summary of our operating expense for the three months ended November 30, 2015 and 2014 follows:

	Three months ended November 30,				Increase/			Percentage
	2015		2014		(Decrease)			Change
Operating expense
Selling, general and administrative	$	380,138	$	408,645	$	(28,507	)		-7
Research and development		147,265		179,321		(32,057	)		-18
Stock compensation		63,214		157,646		(94,432	)		-60
Total operating expense	$	590,616	$	745,612	$	(154,996	)		-21

Selling, General and Administrative

Selling, general and administrative costs include all expenditures incurred other than research and development related costs, including costs related to personnel, professional fees, travel and entertainment, public company costs, insurance and other office related costs. During the three months ended November 30, 2015, we experienced a decrease in professional fees and investor communications related fees offset by increases in travel and general costs.

Research and Development

Research and development ("R&D") costs represent costs incurred to develop our SolarWindow™ technology and are incurred pursuant to our research agreements and agreements with other third party providers and certain internal R&D cost allocations. Payments under these agreements include salaries and benefits for R&D personnel, allocated overhead, contract services and other costs. R&D costs are expensed when incurred, except for non-refundable advance payments for future research and development activities which are capitalized and recognized as expense as the related services are performed. R&D costs decreased during the three months ended November 30, 2015 as a result of slightly more R&D related activity in the prior year.

Stock Compensation

Expense associated with equity based transactions is calculated and expensed in our financial statements as required pursuant to various accounting rules and is non-cash in nature. Stock compensation represents the expense associated with the amortization of our stock options, issuance of common stock and issuance of warrants to purchase our common stock. Stock compensation expense decreased during the three months ended November 30, 2015 compared to the same period last year due to the lack of stock option grants and stock issuances in the current period in addition to the decay of option related compensation expense associated with grants made in prior periods.

Other Income (Expense)

A summary of our other income (expense) for the three months ended November 30, 2015 and 2014 follows:

	Three Months Ended November 30,
	2015			2014			Change
Other income (expense)
Interest expense	$	(70,567	)	$	(55,727	)	$	14,840
Accretion of debt discount		(662,766	)		(2,457,910	)	$	(1,795,144	)
Total other income (expense)	$	(733,333	)	$	(2,513,637	)	$	(1,780,304	)

"Interest expense" relates to the stated interest of our convertible promissory notes and bridge note. "Accretion of debt discount" represents the accretion of the discount applied to our notes as a result of the issuance of detachable warrants and the beneficial conversion feature contained in our notes. The amounts under each column relate to the 2013 Note and amendment thereto and to a lesser extent to the Series L Warrants issued in connection with the $600,000 bridge loan financing on March 4, 2015. See "NOTE 2 - Debt" to our Consolidated Financial Statements contained in this Form 10-Q.

Liquidity and Capital Resources

We have an accumulated deficit of $30,362,963 through November 30, 2015. Included in the deficit are non-cash expenses totaling $11,627,972 relating to the issuance of stock for services, compensatory stock options, warrants granted for value and accretion of debt discount. Due to the "start-up" nature of our business, we expect to incur losses as we continue development of our technologies.

These conditions raise substantial doubt about our ability to continue as a going concern. Management recognizes that in order for us to meet our capital requirements, and continue to operate, additional financing will be necessary. We expect to raise additional funds through private or public equity investment in order to maintain and/or expand the range and scope of our business operations; however, there is no assurance that such additional funds will be available for us on acceptable terms, if at all. If we are unable to raise additional capital when needed or generate positive cash flow, it is unlikely that we will be able to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Our principal source of liquidity is cash in the bank. At November 30, 2015, we had a cash and cash equivalent balance of $169,057 and a commitment to borrow up to $150,000 which was funded on December 22, 2015. We have financed our operations primarily from the sale of equity and debt securities.

Net cash used in operating activities was $457,113 for the three months ended November 30, 2015, compared to net cash used in operating activities of $518,305 for the three months ended November 30, 2014. The decrease in cash used in operating activities of $61,192 substantially reflects decreases in amounts paid for general, administrative and research and development expenses.

Net cash used in investing activities was $2,300 for the three months ended November 30, 2015, compared to net cash used in investing activities of $14,208 for the three months ended November 30, 2014. Cash used in investing activities substantially reflects amounts paid for office equipment.

Net cash provided by financing activities was $400,005 for the three months ended November 30, 2015, compared to $3,242 for the three months ended November 30, 2014. Cash provided by financing activities during the three months ended November 30, 2015 was from the receipt of a bridge loan whereas cash provided by financing activities during the three months ended November 30, 2014 was from the exercise of Series H Stock Purchase Warrants.

Other Contractual Obligations

In addition to our contractual obligations under the research agreements, as of November 30, 2015, we have lease payments of $1,150 each month under our month-to-month corporate and other office operating leases.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements.

Recently Issued Accounting Pronouncements

See Note 1 to our Consolidated Financial Statements for more information regarding recent accounting pronouncements and their impact to our consolidated results of operations and financial position.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act"), as of the end of the period covered by this quarterly report. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that as of May 31, 2015, that our disclosure controls and procedures were effective such that the information required to be disclosed in our United States Securities and Exchange Commission (the "SEC") reports is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 6. Exhibits

Exhibit No.		Description of Exhibit

4.1		Bridge Loan Agreement and Promissory Note by and between the Company and Kalen Capital Corporation dated December 7, 2015 (Incorporated by reference to Form 8-K filed on December 11, 2015)

4.2		Form of Series M Warrant (Incorporated by reference to Form 8-K filed on December 11, 2015)

10.1		Amendment to Bridge Loan Agreement dated December 7, 2015 (Incorporated by reference to Form 8-K filed on December 11, 2015)

31.1		Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*

32.1		Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*

101.INS		XBRL Instance Document**

101.SCH		XBRL Taxonomy Extension Schema Document**

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document**

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document**

101.LAB		XBRL Taxonomy Extension Label Linkbase Document**

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document**

______________________

*	Filed herewith

**	Furnished herewith. XBRL (eXtensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	SolarWindow Technologies, Inc. (Registrant)

Date: January 13, 2016	By:	/s/ John A. Conklin
		John A. Conklin
		Chief Executive Officer, Chief Financial Officer and Director (Principal Executive Officer, Principal Financial Officer, and Principal Accounting Officer)

EXHIBIT 31.1

CERTIFICATION PURSUANT TO RULE 13A-14(A) OF THE SECURITIES EXCHANGE ACT OF 1934
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, John A. Conklin, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of SolarWindow Technologies, Inc. (the "Registrant");

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	As the registrant's certifying officer I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.	As the registrant's certifying officer I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's Board of Directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: January 13, 2016	By:	/s/ John A. Conklin
		John A. Conklin
		Chief Executive Officer, Chief Financial Officer and Director (Principal Executive Officer, Principal Financial Officer, and Principal Accounting Officer)

EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the accompanying Quarterly Report on Form 10-Q of SolarWindow Technologies, Inc. for the fiscal quarter ending November 30, 2015, I, John Conklin, Chief Executive Officer and Chief Financial Officer of SolarWindow Technologies, Inc., hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge and belief, that:

	1.	Such Quarterly Report on Form 10-Q for the fiscal quarter ending November 30, 2015, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	2.	The information contained in such Quarterly Report on Form 10-Q for the fiscal quarter ending November 30, 2015, fairly presents, in all material respects, the financial condition and results of operations of SolarWindow Technologies, Inc.

Date: January 13, 2016	By:	/s/ John A. Conklin
		John A. Conklin
		Chief Executive Officer, Chief Financial Officer and Director (Principal Executive Officer, Principal Financial Officer, and Principal Accounting Officer)

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Nov. 30, 2015	Jan. 07, 2016
Document And Entity Information
Entity Registrant Name	SolarWindow Technologies, Inc.
Entity Central Index Key	0001071840
Document Type	10-Q
Document Period End Date	Nov. 30, 2015
Amendment Flag	false
Current Fiscal Year End Date	--08-31
Is Entity a Well-known Seasoned Issuer	No
Is Entity a Voluntary Filer	No
Is Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		26,944,721
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2016

CONSOLIDATED BALANCE SHEETS - USD ($)	Nov. 30, 2015	Aug. 31, 2015
Current assets
Cash and cash equivalents	$ 169,057	$ 228,465
Deferred research and development costs	23,443	106,135
Prepaid expenses and other current assets	29,020	21,152
Total current assets	221,520	355,752
Equipment, net of accumulated depreciation of $30,531 and $27,751, respectively	30,055	30,535
Total assets	251,575	386,287
Current liabilities
Accounts payable	90,123	97,438
Interest payable to related party	514,065	443,498
Bridge note, net of discount of $0 and $6,516	600,000	593,484
Convertible promissory notes payable to related party, net of discount of $623,558 and $879,808, respectively	2,776,447	2,120,192
Total current liabilities	$ 3,980,635	$ 3,254,612
Stockholders' equity (deficit)
Preferred stock: $0.10 par value; 1,000,000 shares authorized, no shares issued and outstanding
Common stock: $0.001 par value; 300,000,000 shares authorized, 26,572,615 shares issued and outstanding at November 30, 2015 and August 31, 2015	$ 26,572	$ 26,572
Additional paid-in capital	26,607,331	26,144,117
Retained deficit	(30,362,963)	(29,039,014)
Total stockholders' equity (deficit)	(3,729,060)	(2,868,325)
Total liabilities and stockholders' equity (deficit)	$ 251,575	$ 386,287

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Nov. 30, 2015	Aug. 31, 2015
Current assets
Equipment, net of accumulated depreciation	$ 30,531	$ 27,751
Current liabilities
Bridge note, net of discount	0	6,516
Convertible promissory note, net of discount	$ 623,558	$ 879,808
Stockholders' equity
Preferred stock, par value	$ 0.10	$ 0.10
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	26,572,615	26,572,615
Common stock, shares outstanding	26,572,615	26,572,615

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended
	Nov. 30, 2015	Nov. 30, 2014
Consolidated Statements Of Operations
Revenue
Operating expense
Selling, general and administrative	$ 441,694	$ 566,291
Research and development	148,922	179,321
Total operating expense	590,616	745,612
Loss from operations	(590,616)	(745,612)
Other income (expense)
Interest expense	(70,567)	(55,727)
Accretion of debt discount	(662,766)	(2,457,910)
Total other income (expense)	(733,333)	(2,513,637)
Net loss	$ (1,323,949)	$ (3,259,249)
Basic and Diluted Loss per Common Share	$ (0.05)	$ (0.13)
Weighted average number of common shares outstanding - basic and diluted	26,572,615	24,308,495

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Common Stock	Additional Paid-In Capital	Retained Deficit	Total
Beginning Balance, Shares at Aug. 31, 2014	24,306,612
Beginning Balance, Amount at Aug. 31, 2014	$ 24,306	$ 20,872,345	$ (20,946,270)	$ (49,619)
Stock based compensation related to stock issuance, Shares	60,000
Stock based compensation related to stock issuance, Amount	$ 60	83,940		84,000
Stock based compensation due to common stock purchase options		$ 436,774		$ 436,774
Exercise of stock options, Shares
Exercise of stock options, Amount
Discount on convertible promissory note due to detachable warrants		$ 3,000,000		$ 3,000,000
Discount on $600,000 bridge loan due to detachable warrants		299,750		299,750
Exercise of Series H warrants, Shares	1,751,216
Exercise of Series H warrants, Amount	$ 1,751	1,451,763		$ 1,453,514
Exercise of Series G warrants, Shares	454,787
Exercise of Series G warrants, Amount	$ 455	$ (455)
Net loss			$ (8,092,744)	$ (8,092,744)
Ending Balance, Shares at Aug. 31, 2015	26,572,615
Ending Balance, Amount at Aug. 31, 2015	$ 26,572	$ 26,144,117	$ (29,039,014)	$ (2,868,325)
Stock based compensation related to stock issuance, Shares
Stock based compensation related to stock issuance, Amount
Stock based compensation due to common stock purchase options		$ 63,214		$ 63,214
Exercise of stock options, Shares
Exercise of stock options, Amount
Discount on convertible promissory note due to detachable warrants		$ 234,360		$ 234,360
Discount on convertible promissory note due to beneficial conversion feature		$ 165,640		$ 165,640
Discount on $600,000 bridge loan due to detachable warrants
Exercise of Series H warrants, Shares
Exercise of Series H warrants, Amount
Exercise of Series G warrants, Shares
Net loss			$ (1,323,949)	$ (1,323,949)
Ending Balance, Shares at Nov. 30, 2015	26,572,615
Ending Balance, Amount at Nov. 30, 2015	$ 26,572	$ 26,607,331	$ (30,362,963)	$ (3,729,060)

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	3 Months Ended
	Nov. 30, 2015	Nov. 30, 2014
Cash flows from operating activities
Net loss	$ (1,323,949)	$ (3,259,249)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	2,780	1,831
Stock based compensation expense	63,214	157,646
Accretion of debt discount	662,766	$ 2,457,910
Changes in operating assets and liabilities:
Decrease (increase) in deferred research and development costs	82,692
Decrease (increase) in prepaid expenses and other current assets	(7,868)	$ (7,998)
Increase (decrease) in accounts payable	(7,315)	75,828
Increase (decrease) in accrued liabilities	70,567	55,727
Net cash used in operating activities	(457,113)	(518,305)
Cash flows from investing activity
Purchase of equipment	(2,300)	(14,208)
Net cash used in investing activity	$ (2,300)	(14,208)
Cash flows from financing activities
Proceeds from the exercise of warrants		$ 3,242
Proceeds from promissory notes	$ 400,005
Net cash provided by financing activities	400,005	$ 3,242
Decrease in cash and cash equivalents	(59,408)	(529,271)
Cash and cash equivalents at beginning of period	228,465	785,237
Cash and cash equivalents at end of period	$ 169,057	$ 255,966
Supplemental disclosure of cash flow information:
Interest paid in cash
Income taxes paid in cash
Supplemental disclosure of non-cash transactions:
Debt discount recorded for value of warrants issued	$ 234,360	$ 3,000,000
Debt discount recorded for beneficial conversion feature	$ 165,640

Basis of Presentation, Organization, Recent Accounting Pronouncements and Going Concern

3 Months Ended

Nov. 30, 2015

Notes to Financial Statements

Note 1. Basis of Presentation, Organization, Recent Accounting Pronouncements and Going Concern

Basis of Presentation

Organization

On March 9, 2015, the Company changed its name to "SolarWindow Technologies, Inc." in order to appropriately align the corporate name and brand identity. The Company's ticker symbol changed to WNDW.

Recent Accounting Pronouncements

Going Concern

If adequate funds are not available on reasonable terms, or at all, it would result in a material adverse effect on the Company's business, operating results, financial condition and prospects. In particular, the Company may be required to delay, reduce the scope of or terminate its research programs, sell rights to its SolarWindow™ technology and/or MotionPower™ technology or other technologies or products based upon such technologies, or license the rights to such technologies or products on terms that are less favorable to the Company than might otherwise be available.

Debt

3 Months Ended

Nov. 30, 2015

Notes to Financial Statements

Note 2. Debt

December 7, 2015, $550,000 Bridge Loan

March 4, 2015, $600,000 Bridge Loan

Interest expense and accretion of the debt discount related to the March 2015 Loan amounted to $10,835 and $6,516, respectively, during the three months ended November 30, 2015.

Convertible Promissory Note

Interest expense related to the 2013 Loan Agreement as amended amounted to $59,732 and $55,727 during the three months ended November 30, 2015 and 2014, respectively.

Common Stock and Warrants

3 Months Ended

Nov. 30, 2015

Notes to Financial Statements

Note 3. Common Stock and Warrants

During the year ended August 31, 2015, the Company had the following common stock related transactions:

	·	issued 454,787 shares of common stock upon the cashless exercise of 625,000 Series G Warrants.

	·	issued 1,751,216 shares of common stock as a result of the exercise of Series H Warrants for which the Company received $1,453,514.

	·	issued 20,000 shares of common stock on January 26, 2015 to each of the Company's three directors pursuant to the 2006 Plan (60,000 shares total) valued at $1.40 per share, the closing price of the Company's common stock on the day the stock was granted (See "NOTE 6 - Related Party Transactions" below for additional information).

Warrants

	Shares of Common Stock Issuable from Warrants Outstanding as of
Description	November 30, 2015		August 31, 2015		Exercise Price		Expiration
Series G		-		-	$	0.64	April 17, 2015
Series H		3,906		3,906	$	0.83	February 1, 2016
Series I		921,875		921,875	$	1.37	October 7, 2018
Series J		3,110,378		3,110,378	$	1.12	November 9, 2019
Series K		3,110,378		3,110,378	$	1.20	November 9, 2019
Series L		500,000		500,000	$	1.20	March 4, 2020
Total		7,646,537		7,646,537

Stock Options

3 Months Ended

Nov. 30, 2015

Notes to Financial Statements

Note 4. Stock Options

	Year Ended
	August 31, 2015
Expected dividend yield		–
Expected stock price volatility		137.5	%
Risk-free interest rate		1.90	%
Expected term (in years)		7.67
Exercise price	$	1.40
Weighted-average grant date fair-value	$	1.33

A summary of the Company's stock option activity for the three months ended November 30, 2015 and 2014 and related information follows:

	Number of Shares Subject to Option Grants			Weighted Average Exercise Price ($)		Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value ($)
Outstanding at August 31, 2014		1,325,837			2.68
Grants		15,000			1.40
Forfeitures		(73,335	)		2.46
Outstanding at August 31, 2015		1,267,502			2.68
Forfeitures		(16,667	)		5.94
Outstanding at November 30, 2015		1,250,835			2.63	7.21 years	$	651,292
Exercisable at November 30, 2015		693,335			2.43	6.44 years	$	556,417
Available for grant at November 30, 2015		3,332,498

	Three Months Ended November 30,
	2015		2014
Stock Compensation Expense:
Selling general and administrative expense	$	61,556	$	154,133
R&D expense	$	1,658	$	3,513

As of November 30, 2015, the Company had $219,665 of unrecognized compensation cost related to unvested stock options which is expected to be recognized over a period of 2.25 years.

The following table summarizes information about stock options outstanding and exercisable at November 30, 2015:

	Stock Options Outstanding						Stock Options Exercisable
Range of Exercise Prices	Number of Shares Subject to Outstanding Options		Weighted Average Contractual Life (years)		Weighted Average Exercise Price		Number of Shares Subject To Options Exercise		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price
$0.80		15,000		7.06	$	0.80		15,000		7.06	$	0.80
1.40		15,000		9.05		1.40		7,500		9.05		1.40
1.65		320,000		3.98		1.65		320,000		5.77		1.65
2.30		2,500		6.41		2.30		2,500		6.41		2.30
2.50		10,000		5.35		2.50		10,000		5.35		2.50
2.55		33,334		2.78		2.55		33,334		2.78		2.55
2.90		805,000		8.16		2.90		255,000		8.14		2.90
4.98		16,667		2.28		4.98		16,667		2.28		4.98
5.94		33,334		5.07		5.94		33,334		5.07		5.94
Total		1,250,835		7.21	$	2.63		693,335		6.44	$	2.43

Net Loss Per Share

3 Months Ended

Nov. 30, 2015

Notes to Financial Statements

Note 5. Net Loss Per Share

Following is the computation of basic and diluted net loss per share for the three months ended November 30, 2015 and 2014:

	Three Months Ended
	November 30,
	2015			2014
Basic and Diluted EPS Computation
Numerator:
Loss available to common stockholders'	$	(1,323,949	)	$	(3,259,249	)
Denominator:
Weighted average number of common shares outstanding		26,572,615			24,308,495
Basic and diluted EPS	$	(0.05	)	$	(0.13	)

The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented:

Convertible debt		2,541,853			3,248,878
Warrants issuable upon conversion of debt (See "NOTE 2 - Convertible Promissory Note" above)		2,541,853			3,248,878
Warrants		7,646,537			9,518,851
Stock options		1,250,835			1,314,170
Total shares not included in the computation of diluted losses per share		13,981,078			17,330,777

Related Party Transactions

3 Months Ended

Nov. 30, 2015

Notes to Financial Statements

Note 6. Related Party Transactions

All related party transactions are recorded at the exchange amount established and agreed to between related parties and are in the normal course of business.

Subsequent Events

3 Months Ended

Nov. 30, 2015

Notes to Financial Statements

Note 7. Subsequent Events

Management has reviewed material events subsequent of the quarterly period ended November 30, 2015 and prior to the filing of financial statements in accordance with FASB ASC 855 "Subsequent Events".

December 7, 2015, $550,000 Bridge Loan

March 2015 $600,000 Loan Amendment and Related Warrant Transactions

2015 Loan Agreement

	·	Series I Warrant to purchase 921,875 shares of common stock; maturity date extended from October 6, 2018 to December 31, 2020;

	·	Series J Warrant to purchase 3,110,378 shares of common stock; maturity date extended from November 9, 2019 to December 31, 2020;

	·	Series K Warrant to purchase 3,110,378 shares of common stock; maturity date extended from November 9, 2019 to December 31, 2020; and

	·	Series M Warrant to purchase 275,000 shares of common stock; maturity date extended from December 7, 2020 to December 31, 2020.

Exercise of Stock Purchase Options

On December 17, 2015, John Conklin, the Company's President & CEO, exercised 400,000 stock purchase options on a cashless basis resulting in the issuance of 195,139 shares of common stock.

On December 18, 2015, Joseph Sierchio, a director, exercised 86,670 stock purchase options on a cashless basis resulting in the issuance of 47,567 shares of common stock.

On December 18, 2015, Alastair Livesey, a director, exercised 70,000 stock purchase options on a cashless basis resulting in the issuance of 39,400 shares of common stock.

Modification #7 to the Cooperative Research and Development Agreement with

Director Stock Awards

Basis of Presentation, Organization, Recent Accounting Pronouncements and Going Concern (Policies)	3 Months Ended
	Nov. 30, 2015
Basis Of Presentation Organization Recent Accounting Pronouncements And Going Concern Policies
Basis of Presentation	The unaudited financial statements of SolarWindow Technologies, Inc. (the "Company") as of November 30, 2015, and for the three months ended November 30, 2015 and 2014, have been prepared in accordance with accounting principles generally accepted in the United States for interim financial reporting and include the Company's wholly-owned subsidiaries, Kinetic Energy Corporation ("KEC"), and New Energy Solar Corporation ("New Energy Solar"). Accordingly, they do not include all of the disclosures required by accounting principles generally accepted in the United States for complete financial statements and should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended August 31, 2015, as filed with the Securities and Exchange Commission as part of the Company's Form 10-K. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the interim financial information have been included. The Company did not record an income tax provision during the periods presented due to net taxable losses. The results of operations for any interim period are not necessarily indicative of the results of operations for the entire year.
Organization	SolarWindow Technologies, Inc. was incorporated in the State of Nevada on May 5, 1998, under the name "Octillion Corp." On December 2, 2008, the Company amended its Articles of Incorporation to effect a change of name to New Energy Technologies, Inc. Effective as of March 9, 2015, the Company amended its Articles of Incorporation to change its name to SolarWindow Technologies, Inc. The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Kinetic Energy Corporation ("KEC") and New Energy Solar Corporation. KEC was incorporated on June 19, 2008, in the State of Nevada and holds the patents related to the Company's MotionPower™ technology. The Company's business activities related to the MotionPower™ technology are conducted through KEC. New Energy Solar was incorporated on February 9, 2009, in the State of Florida and entered into agreements with The University of South Florida Research Foundation ("USF") to sponsor research related to the Company's SolarWindow™ technology. On February 18, 2015, the Company terminated the license agreement entered into with USF which originated on June 21, 2010. On March 9, 2015, the Company changed its name to "SolarWindow Technologies, Inc." in order to appropriately align the corporate name and brand identity. The Company's ticker symbol changed to WNDW. The Company has been developing two (2) sustainable electricity generating systems. These novel technologies are branded as SolarWindow™ and MotionPower™. On March 2, 2015, the Company announced its exclusive focus on SolarWindow™. The Company's SolarWindow™ technology provides the ability to harvest light energy from the sun and artificial sources and generate electricity from a see-through, semi-transparent, coating of organic photovoltaic solar cells. The Company's SolarWindow™ transparent electricity generating coatings are the subject of patent pending technologies. Initially being developed for application on glass surfaces, SolarWindow™ coatings could potentially be used on any of the more than 85 million commercial and residential buildings in the United States alone. The Company's SolarWindow™ product development programs involve ongoing research and development efforts, and the commitment of significant resources to support the extensive invention, design, engineering, testing, prototyping, and intellectual property initiatives carried-out by its contract engineers, scientists, and consultants. As such, the Company's activities are subject to significant risks and uncertainties, including failing to secure additional funding to operationalize the Company's technology before another company develops similar technology and products.
Recent Accounting Pronouncements	In February 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2015-02, "Amendments to the Consolidation Analysis", which amends the consolidation requirements in ASC 810 and significantly changes the consolidation analysis required under U.S. GAAP relating to whether or not to consolidate certain legal entities. Early adoption is permitted. The Company's effective date for adoption is January 1, 2016. The Company does not expect this accounting update to have a material effect on its consolidated financial statements in future periods, although that could change. In January 2015, the FASB issued ASU 2015-01, "Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items", which eliminates the concept from U.S. GAAP the concept of an extraordinary item. Under the ASU, an entity will no longer (1) segregate an extraordinary item from the results of ordinary operations; (2) separately present an extraordinary item on its income statement, net of tax, after income from continuing operations; or (3) disclose income taxes and earnings-per-share data applicable to an extraordinary item. Early adoption is permitted. The Company's effective date for adoption is January 1, 2016. The Company does not expect this accounting update to have a material effect on its consolidated financial statements in future periods, although that could change. In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205 40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern, which is intended to define management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosures. Specifically, ASU 2014-15 provides a definition of the term substantial doubt and requires an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). It also requires certain disclosures when substantial doubt is alleviated as a result of consideration of management's plans and requires an express statement and other disclosures when substantial doubt is not alleviated. The new standard will be effective for reporting periods beginning after December 15, 2016, with early adoption permitted. Management does not expect the adoption of ASU 2014-15 to have a material impact on our financial statements and disclosures. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (ASU 2014-09), which supersedes most existing revenue recognition guidance under US GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP. The standard is effective for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company does not expect this accounting update to have a material effect on its consolidated financial statements in future periods. The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Company's previous fiscal year may be applicable, the Company has not identified any standards that the Company believes merit further discussion. The Company believes that none of the new standards will have a significant impact on the financial statements.
Going Concern	The Company does not have any commercialized products and has not generated any revenue since inception. The Company has an accumulated deficit of $30,362,963 as of November 30, 2015, and does not have positive cash flows from operating activities. The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America, which contemplates continuation of the Company as a going concern, which is dependent upon the Company's ability to establish itself as a profitable business. In its report with respect to the Company's financial statements for the year ended August 31, 2015, the Company's independent auditors expressed substantial doubt about the Company's ability to continue as a going concern. Because the Company has not yet generated revenues from its operations and does not expect to do so in the near future, its ability to continue as a going concern is wholly dependent upon its ability to obtain additional financing. Currently, the Company is seeking additional financing but has no commitments to obtain any such financing, and there can be no assurance that financing will be available in amounts or on terms acceptable to the Company, if at all. As of November 30, 2015, the Company had cash of $169,057 and commitments for an additional loan of $150,000. Based upon its current and near term anticipated level of operations and expenditures, the Company believes that cash on hand should be sufficient to enable it to continue operations through January 2016. If adequate funds are not available on reasonable terms, or at all, it would result in a material adverse effect on the Company's business, operating results, financial condition and prospects. In particular, the Company may be required to delay, reduce the scope of or terminate its research programs, sell rights to its SolarWindow™ technology and/or MotionPower™ technology or other technologies or products based upon such technologies, or license the rights to such technologies or products on terms that are less favorable to the Company than might otherwise be available. In view of these conditions, the ability of the Company to continue as a going concern is in substantial doubt and dependent upon achieving a profitable level of operations and on the ability of the Company to obtain necessary financing to fund ongoing operations. These consolidated financial statements do not give effect to any adjustments which will be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying consolidated financial statements.

Common Stock and Warrants (Tables)

3 Months Ended

Nov. 30, 2015

Common Stock And Warrants Tables

Warrants outstanding and exercisable

A summary of the Company's warrants outstanding and exercisable as of November 30, 2015 and August 31, 2015 is as follows:

	Shares of Common Stock Issuable from Warrants Outstanding as of
Description	November 30, 2015		August 31, 2015		Exercise Price		Expiration
Series G		-		-	$	0.64	April 17, 2015
Series H		3,906		3,906	$	0.83	February 1, 2016
Series I		921,875		921,875	$	1.37	October 7, 2018
Series J		3,110,378		3,110,378	$	1.12	November 9, 2019
Series K		3,110,378		3,110,378	$	1.20	November 9, 2019
Series L		500,000		500,000	$	1.20	March 4, 2020
Total		7,646,537		7,646,537

Stock Options (Tables)

3 Months Ended

Nov. 30, 2015

Stock Options Tables

Fair value of each option award

	Year Ended
	August 31, 2015
Expected dividend yield		–
Expected stock price volatility		137.5	%
Risk-free interest rate		1.90	%
Expected term (in years)		7.67
Exercise price	$	1.40
Weighted-average grant date fair-value	$	1.33

Stock option activity

A summary of the Company's stock option activity for the three months ended November 30, 2015 and 2014 and related information follows:

	Number of Shares Subject to Option Grants			Weighted Average Exercise Price ($)		Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value ($)
Outstanding at August 31, 2014		1,325,837			2.68
Grants		15,000			1.40
Forfeitures		(73,335	)		2.46
Outstanding at August 31, 2015		1,267,502			2.68
Forfeitures		(16,667	)		5.94
Outstanding at November 30, 2015		1,250,835			2.63	7.21 years	$	651,292
Exercisable at November 30, 2015		693,335			2.43	6.44 years	$	556,417
Available for grant at November 30, 2015		3,332,498

Share-based compensation cost

	Three Months Ended November 30,
	2015		2014
Stock Compensation Expense:
Selling general and administrative expense	$	61,556	$	154,133
R&D expense	$	1,658	$	3,513

Stock options outstanding and exercisable

The following table summarizes information about stock options outstanding and exercisable at November 30, 2015:

	Stock Options Outstanding						Stock Options Exercisable
Range of Exercise Prices	Number of Shares Subject to Outstanding Options		Weighted Average Contractual Life (years)		Weighted Average Exercise Price		Number of Shares Subject To Options Exercise		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price
$0.80		15,000		7.06	$	0.80		15,000		7.06	$	0.80
1.40		15,000		9.05		1.40		7,500		9.05		1.40
1.65		320,000		3.98		1.65		320,000		5.77		1.65
2.30		2,500		6.41		2.30		2,500		6.41		2.30
2.50		10,000		5.35		2.50		10,000		5.35		2.50
2.55		33,334		2.78		2.55		33,334		2.78		2.55
2.90		805,000		8.16		2.90		255,000		8.14		2.90
4.98		16,667		2.28		4.98		16,667		2.28		4.98
5.94		33,334		5.07		5.94		33,334		5.07		5.94
Total		1,250,835		7.21	$	2.63		693,335		6.44	$	2.43

Net Loss Per Share (Tables)

3 Months Ended

Nov. 30, 2015

Net Loss Per Share Tables

Computation of basic and diluted net loss per share

Following is the computation of basic and diluted net loss per share for the three months ended November 30, 2015 and 2014:

	Three Months Ended
	November 30,
	2015			2014
Basic and Diluted EPS Computation
Numerator:
Loss available to common stockholders'	$	(1,323,949	)	$	(3,259,249	)
Denominator:
Weighted average number of common shares outstanding		26,572,615			24,308,495
Basic and diluted EPS	$	(0.05	)	$	(0.13	)

The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented:

Convertible debt		2,541,853			3,248,878
Warrants issuable upon conversion of debt (See "NOTE 2 - Convertible Promissory Note" above)		2,541,853			3,248,878
Warrants		7,646,537			9,518,851
Stock options		1,250,835			1,314,170
Total shares not included in the computation of diluted losses per share		13,981,078			17,330,777

Basis of Presentation, Organization, Recent Accounting Pronouncements and Going Concern (Details Narrative) - USD ($)	Nov. 30, 2015	Aug. 31, 2015	Nov. 30, 2014	Aug. 31, 2014
Organization And Going Concern Details Narrative
Accumulated deficit	$ 30,362,963	$ 29,039,014
Cash and cash equivalents	$ 169,057	$ 228,465	$ 255,966	$ 785,237

Debt (Details Narrative) - USD ($)	3 Months Ended
Debt (Details Narrative) - USD ($)	Nov. 30, 2015	Nov. 30, 2014
Interest expense	$ 70,567	$ 55,727
Accretion of debt discount	662,766	2,457,910
Convertible Promissory Note [Member]
Interest expense	59,732	55,727
Accretion of debt discount	656,250	$ 2,457,910
Bridge Loan [Member]
Interest expense	10,835
Accretion of debt discount	$ 6,516

Common Stock and Warrants (Details) - $ / shares	3 Months Ended
Common Stock and Warrants (Details) - $ / shares	Nov. 30, 2015	Aug. 31, 2015
Shares of Common Stock Issuable from Warrants	7,646,537	7,646,537
Series J [Member]
Shares of Common Stock Issuable from Warrants		3,110,378
Series K [Member]
Shares of Common Stock Issuable from Warrants		3,110,378
Series L [Member]
Shares of Common Stock Issuable from Warrants		500,000
Series G [Member]
Shares of Common Stock Issuable from Warrants
Exercise Price	$ 0.64
Expiration	Apr. 17, 2015
Series H [Member]
Shares of Common Stock Issuable from Warrants	3,906	3,906
Exercise Price	$ 0.83
Expiration	Feb. 01, 2016
Series I [Member]
Shares of Common Stock Issuable from Warrants	921,875	921,875
Exercise Price	$ 1.37
Expiration	Oct. 07, 2018
Series J [Member]
Shares of Common Stock Issuable from Warrants	3,110,378
Exercise Price	$ 1.12
Expiration	Nov. 09, 2019
Series K [Member]
Shares of Common Stock Issuable from Warrants	3,110,378
Exercise Price	$ 1.2
Expiration	Nov. 09, 2019
Series L [Member]
Shares of Common Stock Issuable from Warrants	500,000
Exercise Price	$ 1.2
Expiration	Mar. 04, 2020

Common Stock and Warrants (Details Narrative) - USD ($)	3 Months Ended
Common Stock and Warrants (Details Narrative) - USD ($)	Nov. 30, 2015	Nov. 30, 2014	Aug. 31, 2015
Common stock, shares authorized	300,000,000		300,000,000
Common stock, par value	$ 0.001		$ 0.001
Common stock, shares outstanding	26,572,615		26,572,615
Amount received upon the exercise of warrants		$ 3,242
Series H [Member]
Common stock, shares issued during period	1,751,216
Amount received upon the exercise of warrants	$ 1,453,514
Series G [Member]
Common stock, shares issued during period	454,787
Warrants exercised	625,000
2006 Long-Term Incentive Plan [Member]
Common stock, shares authorized	300,000,000
Common stock, par value	$ 0.001
Common stock, shares outstanding	26,572,615
Stock reserved	3,332,498

Stock Options (Details) - USD ($)	3 Months Ended	12 Months Ended
Stock Options (Details) - USD ($)	Nov. 30, 2014	Aug. 31, 2015
Stock Options Details
Expected dividend yield
Expected stock price volatility		137.50%
Risk-free interest rate		1.90%
Expected term (in years)		7 years 8 months 1 day
Exercise price	$ 1.40	$ 1.40
Weighted-average grant date fair-value		$ 1.33

Stock Options (Details 1) - USD ($)	3 Months Ended		12 Months Ended
Stock Options (Details 1) - USD ($)	Nov. 30, 2015	Nov. 30, 2014	Aug. 31, 2015
Number of Options
Outstanding Beginning		1,325,837	1,325,837
Grants		15,000
Forfeitures	(16,667)	(73,335)
Outstanding Ending	1,250,835	1,267,502
Exercisable Ending	693,335
Available for grant Ending	3,332,498
Weighted Average Exercise Price ($)
Weighted-average exercise price Beginning		$ 2.68	$ 2.68
Grants		1.40	$ 1.40
Forfeitures	$ 5.94	2.46
Weighted-average exercise price Ending	2.63	$ 2.68
Exercisable Ending	$ 2.43
Weighted Average Remaining Contractual Term
Outstanding Ending	7 years 2 months 16 days
Exercisable Ending	6 years 5 months 9 days
Aggregate Intrinsic Value ($)
Outstanding Ending	$ 651,292
Exercisable Ending	$ 556,417

Stock Options (Details 2) - USD ($)	3 Months Ended
Stock Options (Details 2) - USD ($)	Nov. 30, 2015	Nov. 30, 2014
Stock Compensation Expense:
Selling, general and administrative	$ 61,556	$ 154,133
Research and development	$ 1,658	$ 3,513

Stock Options (Details 3) - $ / shares	3 Months Ended
Stock Options (Details 3) - $ / shares	Nov. 30, 2015	Nov. 30, 2014	Aug. 31, 2014
Number of Shares Subject to Outstanding Options	1,250,835	1,267,502	1,325,837
Weighted average contractural life (years)	7 years 2 months 16 days
Weighted-average exercise price	$ 2.63	$ 2.68	$ 2.68
Number of Shares Subject to options exercisable	693,335
Weighted average contractural life (years) of options exercisable	6 years 5 months 9 days
Weighted-average exercise price of options exercisable	$ 2.43
$0.80 Per Share [Member]
Number of Shares Subject to Outstanding Options	15,000
Weighted average contractural life (years)	7 years 22 days
Weighted-average exercise price	$ 0.80
Number of Shares Subject to options exercisable	15,000
Weighted average contractural life (years) of options exercisable	7 years 22 days
Weighted-average exercise price of options exercisable	$ 0.80
$1.40 Per Share [Member]
Number of Shares Subject to Outstanding Options	15,000
Weighted average contractural life (years)	9 years 18 days
Weighted-average exercise price	$ 1.40
Number of Shares Subject to options exercisable	7,500
Weighted average contractural life (years) of options exercisable	9 years 18 days
Weighted-average exercise price of options exercisable	$ 1.40
$1.65 Per Share [Member]
Number of Shares Subject to Outstanding Options	320,000
Weighted average contractural life (years)	3 years 11 months 23 days
Weighted-average exercise price	$ 1.65
Number of Shares Subject to options exercisable	320,000
Weighted average contractural life (years) of options exercisable	5 years 9 months 7 days
Weighted-average exercise price of options exercisable	$ 1.65
$2.30 Per Share [Member]
Number of Shares Subject to Outstanding Options	2,500
Weighted average contractural life (years)	6 years 4 months 28 days
Weighted-average exercise price	$ 2.30
Number of Shares Subject to options exercisable	2,500
Weighted average contractural life (years) of options exercisable	6 years 4 months 28 days
Weighted-average exercise price of options exercisable	$ 2.30
$2.50 Per Share [Member]
Number of Shares Subject to Outstanding Options	10,000
Weighted average contractural life (years)	5 years 4 months 6 days
Weighted-average exercise price	$ 2.50
Number of Shares Subject to options exercisable	10,000
Weighted average contractural life (years) of options exercisable	5 years 4 months 6 days
Weighted-average exercise price of options exercisable	$ 2.50
$2.55 Per Share [Member]
Number of Shares Subject to Outstanding Options	33,334
Weighted average contractural life (years)	2 years 9 months 11 days
Weighted-average exercise price	$ 2.55
Number of Shares Subject to options exercisable	33,334
Weighted average contractural life (years) of options exercisable	2 years 9 months 11 days
Weighted-average exercise price of options exercisable	$ 2.55
$2.90 Per Share [Member]
Number of Shares Subject to Outstanding Options	805,000
Weighted average contractural life (years)	8 years 1 month 28 days
Weighted-average exercise price	$ 2.90
Number of Shares Subject to options exercisable	255,000
Weighted average contractural life (years) of options exercisable	8 years 1 month 21 days
Weighted-average exercise price of options exercisable	$ 2.90
$4.98 Per Share [Member]
Number of Shares Subject to Outstanding Options	16,667
Weighted average contractural life (years)	2 years 3 months 11 days
Weighted-average exercise price	$ 4.98
Number of Shares Subject to options exercisable	16,667
Weighted average contractural life (years) of options exercisable	2 years 3 months 11 days
Weighted-average exercise price of options exercisable	$ 4.98
$5.94 Per Share [Member]
Number of Shares Subject to Outstanding Options	33,334
Weighted average contractural life (years)	5 years 26 days
Weighted-average exercise price	$ 5.94
Number of Shares Subject to options exercisable	33,334
Weighted average contractural life (years) of options exercisable	5 years 26 days
Weighted-average exercise price of options exercisable	$ 5.94

Stock Options (Details Narrative) - USD ($)	3 Months Ended
Stock Options (Details Narrative) - USD ($)	Nov. 30, 2015	Aug. 31, 2015
Stock option available for grant shares	3,332,498
Closing stock option exercise price	$ 3.05
Stock option outstanding	1,200,834
Stock based compensation unrecognized	$ 219,665
Expected period for recognition	2 years 3 months
2006 Incentive Stock Option Plan [Member]
Stock option approved		5,000,000
Stock option available for grant shares		3,332,498
Stock option exercise		326,667

Net Loss Per Share (Details) - USD ($)	3 Months Ended		12 Months Ended
Net Loss Per Share (Details) - USD ($)	Nov. 30, 2015	Nov. 30, 2014	Aug. 31, 2015
Numerator:
Loss available to common stockholders'	$ (1,323,949)	$ (3,259,249)	$ (8,092,744)
Denominator:
Weighted average number of common shares outstanding	26,572,615	24,308,495
Basic and diluted EPS	$ (0.05)	$ (0.13)
The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented:
Convertible debt	2,541,853	3,248,878
Warrants issuable upon conversion of debt	2,541,853	3,248,878
Warrants	7,646,537	9,518,851
Stock options	1,250,835	1,314,170
Total shares not included in the computation of diluted losses per share	13,981,078	17,330,777

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended
	Nov. 30, 2015	Nov. 30, 2014
Accounts payable	$ 15,000
Sierchio & Partners, LLP [Member]
Net compensation expense	63,214	$ 152,083
Legal services	$ 46,965	$ 48,910